Form 8-K - Current report:
SEC Accession No. 0001213900-25-056209
Filing Date
2025-06-20
Accepted
2025-06-20 16:20:18
Documents
15
Period of Report
2025-06-20
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0246257-8k_pasithea.htm   iXBRL 8-K 29510
2 OPINION OF LOWENSTEIN SANDLER LLP ea024625701ex5-1_pasithea.htm EX-5.1 9007
3 GRAPHIC ex5-1_001.jpg GRAPHIC 10792
  Complete submission text file 0001213900-25-056209.txt   268331

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ktta-20250620.xsd EX-101.SCH 3809
5 XBRL DEFINITION FILE ktta-20250620_def.xml EX-101.DEF 26680
6 XBRL LABEL FILE ktta-20250620_lab.xml EX-101.LAB 36818
7 XBRL PRESENTATION FILE ktta-20250620_pre.xml EX-101.PRE 25304
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0246257-8k_pasithea_htm.xml XML 5937
Mailing Address 1111 LINCOLN ROAD, SUITE 500 MIAMI BEACH FL 33139
Business Address 1111 LINCOLN ROAD, SUITE 500 MIAMI BEACH FL 33139 (702) 514-4174
Pasithea Therapeutics Corp. (Filer) CIK: 0001841330 (see all company filings)

EIN.: 851591963 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40804 | Film No.: 251061645
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)